Method for patient stratification and drug efficacy monitoring
AssigneeNew York University
InventorsHeather L. Bowling, Aditi Bhattacharya, Eric Klann
Life of this patent
Estimating the term…
Abstract
Identified are markers whose de novo synthesis or levels in blood provide are correlative information on the status of pathology, regardless of whether or not they correlate with the status in the relevant organ. The de novo synthesis or levels in blood can be used for patient stratification and monitoring the efficacy of treatment of diseases, such as fragile X syndrome.
Claims4
A panel consisting of antibodies for the detection of protein markers metabotropic glutamate receptor 5 (mGLUR5), glutamate ionotropic receptor NMDA type subunit 2B (Grin2B), Ras, hexokinase, aconitase 2 (ACO2), eukaryotic translation initiation factor 2a (eIF2a), serine-threonine protein kinase (PAK), synaptic Ras GTPase-activating protein 1 (Syngap), and acyl-CoA-binding protein (DBI), which markers are indicative of the status of fragile X syndrome, each said antibody being specific for mGLUR5, Grin2B, Ras, hexokinase, ACO2, eIF2a, PAK, Syngap, or DBI.
A panel consisting of antibodies for the detection of protein markers aconitase 2 (ACO2), Ras, hexokinase, and metabotropic glutamate receptor 5 (mGLUR5) and glutamate ionotropic receptor NMDA type subunit 2B (Grin2B), which markers are indicative of the status of fragile X syndrome, each said antibody being specific for ACO2, Ras, hexokinase, Grin2B, or mGLUR5.
A panel consisting of antibodies for the detection of protein markers aconitase 2 (ACO2), Ras, and hexokinase, which markers are indicative of the status of fragile X syndrome, each said antibody being specific for ACO2, Ras, or hexokinase.
A panel of antibodies consisting of antibodies for the detection of protein markers:
- i) aconitase 2 (ACO2), ii) Ras, iii) hexokinase, and iv) metabotropic glutamate receptor 5 (mGLUR5) or glutamate ionotropic receptor NMDA type subunit 2B (Grin2B);
- which markers are indicative of the status of fragile X syndrome, each said antibody being specific for ACO2, Ras, hexokinase, mGLUR5 or Grin2B.
Dependencies are inferred from the claim text.